POP Biotechnologies develops platform technologies addressing critical needs in oncology and infectious disease

The Power of PoP

POP BIO uses two patented porphyrin-phospholipid (PoP) liposome technologies to create nanomedicines to address needs in oncology and infectious disease

1.) The Spontaneous Nanoliposome Antigen Particleization (SNAP) platform enables the rapid development of highly immunogenic vaccines

2.) Chemophototherapy (CPT) using PoP liposomes to deliver targeted concentrations of chemotherapy drugs to tumors expose to specific laser light.

Learn more about our technologies

Latest News

October 8, 2021

POP BIO awarded $599,981 Phase 1 SBIR Award to Develop Thermostable COVID-19 Vaccine

BUFFALO, N.Y. — POP Biotechnologies Inc. (POP BIO) received a $599,981, two-year Phase I Small Business Innovation Research (SBIR) under Award No. 1R43AI165089-01, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to pursue development of a potentially life-saving vaccine technology to address the ongoing pandemic crisis caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the microbe responsible for the coronavirus disease 2019 (COVID-19), through the development of a thermostable recombinant nanoparticle vaccine.
February 23, 2021

COVID-19 vaccine developed by UB startup approved for human trials

EuCorVac-19, a next-generation particle-based COVID-19 vaccine incorporating POP BIO's SNAP technology has gained regulatory approval for Phase I/II studies
January 16, 2021

EuCorVac-19 gains regulatory approval for Phase I / II clinical studies

SNAP-based EuBiologics EuCorVac-19 gains regulatory approval for Phase I/II trials in Korea EuBiologics (KOSDAQ: 206650) got an IND approval for Phase I/II clinical trial of a […]